Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
Want to see WHWK full AI Analyst Report?
WHWK Stock Chart & Stats
$4.11
--
Market closed
$4.11
--
Day’s Range― - ―
52-Week Range$1.57 - $5.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.35M
Market Cap
$198.80M
Enterprise Value$198.63M
Total Cash (Recent Filing)$145.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 12, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding49,452,460
10 Day Avg. Volume9,835,549
30 Day Avg. Volume3,352,856
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue27.80
Enterprise Value/Gross Profit31.13
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$7.33Price Target Upside78.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stronger Equity BaseZero debt and a materially stronger equity base materially reduce financial risk and preserve strategic optionality. Over the next 2–6 months this balance-sheet flexibility supports continued R&D and clinical programs without immediate solvency pressure, improving the firm's ability to pursue milestone-driven value creation.
Meaningful PIPE Financing Extends RunwayThe $87.5M PIPE materially lengthens cash runway and reduces near-term refinancing risk, allowing management to fund planned INDs and dose-escalation studies. Significant insider participation aligns incentives and signals confidence, increasing the likelihood the company can reach clinical inflection points before requiring additional dilutive financing.
Expanding CPT113 ADC Platform With External ValidationSecuring broader rights to CPT113 and planning multiple INDs diversifies the pipeline and concentrates expertise around a core linker-payload technology. External Phase 1 data and third-party programs using CPT113 provide validation that can de-risk development pathways and improve long-term commercial prospects if clinical data continue to be favorable.
Bears Say
Significant And Persistent Cash BurnVery large negative operating and free cash flows indicate the business is consuming capital at a high rate, meaning ongoing reliance on external financing. Persistent cash burn erodes optionality, increases dilution risk, and places pressure on management to deliver clinical milestones or secure further capital within the medium term to sustain operations.
Deep Operating Losses And Negative MarginsExtremely negative margins signal structural unprofitability driven by high operating costs relative to revenues. Even with improved gross margins, the company remains far from break-even, meaning profitability is contingent on successful product development and scaling—outcomes that are uncertain and could take multiple years to realize.
Revenue Collapse And Negative Returns On EquityA sharp revenue decline combined with negative ROE reflects deteriorating top-line momentum and value destruction despite a stronger equity base. This undermines long-term growth credibility and suggests the company will struggle to generate acceptable investor returns unless it stabilizes revenues or achieves high-value clinical successes.
Whitehawk Therapeutics News
WHWK FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was $1.57 and its highest was $5.50 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is $198.80M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 62 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on May 07, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.038.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 49,452,460 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went down -5.06%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in WHWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.33 (78.43% Upside)
$7.33 (78.43% Upside)
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.79%
12-Months-Change
Fundamentals
Return on Equity
-79.63%
Trailing 12-Months
Asset Growth
-45.63%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
WHWK Stock 12 Month Forecast
Average Price Target
$7.33
▲(78.43% Upside)
Technical Analysis
Ownership Overview
27.82% Insiders
3.96% Mutual Funds
59.00% Other Institutional Investors
6.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---